Duncker Streett & Co. Inc. Acquires 2,566 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Duncker Streett & Co. Inc. boosted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 22.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,053 shares of the biotechnology company's stock after acquiring an additional 2,566 shares during the period. Axon Enterprise accounts for 1.5% of Duncker Streett & Co. Inc.'s investment portfolio, making the stock its 16th biggest holding. Duncker Streett & Co. Inc.'s holdings in Axon Enterprise were worth $7,391,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of AXON. Fourth Dimension Wealth LLC bought a new stake in shares of Axon Enterprise in the fourth quarter valued at about $30,000. Elequin Capital LP bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $46,000. CoreFirst Bank & Trust bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $59,000. Global Financial Private Client LLC raised its stake in shares of Axon Enterprise by 11,100.0% in the first quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 111 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in Axon Enterprise in the first quarter worth $77,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Trading Up 1.4%

AXON traded up $11.01 during mid-day trading on Tuesday, reaching $794.25. The stock had a trading volume of 743,378 shares, compared to its average volume of 533,953. The stock has a market capitalization of $61.83 billion, a P/E ratio of 191.85, a P/E/G ratio of 90.16 and a beta of 1.29. Axon Enterprise, Inc has a 52 week low of $279.02 and a 52 week high of $806.64. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83. The firm's fifty day simple moving average is $700.64 and its two-hundred day simple moving average is $627.10.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the business posted $1.15 earnings per share. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent research reports. Bank of America increased their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Needham & Company LLC raised their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $699.55.

Insider Transactions at Axon Enterprise

In other news, CFO Brittany Bagley sold 3,400 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the transaction, the chief financial officer now directly owns 131,833 shares in the company, valued at $92,283,100. This represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua Isner sold 905 shares of the firm's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total transaction of $702,632.95. Following the completion of the transaction, the president now directly owns 268,735 shares of the company's stock, valued at $208,643,166.65. This represents a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,642 shares of company stock worth $30,500,428. 5.70% of the stock is currently owned by company insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.